Uric acid levels and vascular disease

Current Medical Research and Opinion

Volumn 20, Issue 6, 2004, Pages 951-954

  Daskalopoulou, S S ^a   Athyros, V G ^b   Elisaf, M ^c   Mikhailidis, Dimitri P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atorvastatin; Diuretics; Fenofibrate; Losartan; Simvastatin; Uric acid; Vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; SIBUTRAMINE; SIMVASTATIN; STATINE DERIVATIVE; TETRAHYDROLIPSTATIN; URIC ACID;

ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; REVIEW; URIC ACID BLOOD LEVEL; VASCULAR DISEASE;

ANTILIPEMIC AGENTS; DIURETICS; GREECE; HUMANS; RISK FACTORS; URIC ACID; VASCULAR DISEASES;

EID: 2442513706     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003971     Document Type: Review

References (47)

1. Alderman M, Aiyer KJV. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79
2. Dahlof B, Devereux RB, Kjeldsen SE, et al. [LIFE Study Group]. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
3. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002;53:493-502
4. Collins R, Armitage J, Parish S, Sleigh P, Peto R. [Heart Protection Study Collaborative Group]. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
5. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. J Clin Pathol [in press]
6. Athyros VG, Elisaf M, Papageorgiou AA, et al. [GREACE Study Collaborative Group]. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
7. Athyros VG, Papageorgiou AA, Elisaf M, et al. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003;19:615-7
8. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004;55:53-62
9. Youssef F, Seifalian AM, Jagroop IA, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002;23:358-64
10. Mosenkis A, Townsend RR. Antihypertensive medications and weight gain. J Clin Hypertens 2004;6:90
11. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. [For the LIFE study group]. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86
12. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goals versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;4:220-8
13. Athyros VG, Papageorgiou AA, Symeonidis AN, et al. [for the GREACE study collaborative Group]. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
14. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. [Cholesterol and Recurrent Events Trial Investigators]. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003;14:1605-13
15. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76
16. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003;42:321-5
17. Achimastos A, Liberopoulos E, Nikas S, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002;18:59-63
18. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34:60-3
19. Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol 2003;43:825-30
20. Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis 1996;27:701-8
21. Chanard J, Toupance O, Lavaud S, et al. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003;18:2147-53
22. Hulthen UL, Katzman PL. Renal effects of acute and long-term treatment with felodipine in essential hypertension. J Hypertens 1988;6:231-7
23. Gostick NK, Mayhew SR, Mukerji D, et al. A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the General Practitioner Hypertension Study Group. J Hum Hypertens 1989;3:141-4
24. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71
25. Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987;1:29-38
26. Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man. Clin Sci (Lond) 1996;90:205-13
27. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995;39:471-6
28. Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. Eur J Endocrinol 1998;138:63-9
29. Vuorinen-Markkola H, Yki-Jarvinen H. Hyperuricemia and insulin resistance. J Clin Endocrinol Metab 1994;78:25-9
30. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology [in press]
31. Quinones Galvan A, Natali A, Baldi S, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol 1995;268:E1-5
32. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55
33. Fruehwald-Schultes B, Oltmanns KM, Toschek B, et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism 2002;51:531-6
34. Kilo C, Dudley J, Kalb B. Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991;14(Suppl 2):S79-82
35. Skillman TG, Feldman JM. The pharmacology of sulfonylureas. Am J Med 1981;70:361-72
36. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-8
37. Daskalopoulou SS, Mikhailidis DP, Athyros VG, Papageorgiou AA, Elisaf M. Fenofibrate and losartan. Ann Rheum Dis 2004;63:469-70
38. Bonora E, Targher G, Zenere MB, et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord 1996;20:975-80
39. Bengtsson C, Lapidus L, Stendahl C, Waldenstrom J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224:549-55
40. Ferraccioli G, Spisni A, Ambanelli U. Hypouricemic action of diflunisal in gouty patients: in vitro and in vivo studies. J Rheumatol 1984;11:330-2
41. Tiitinen S, Nissila M, Ruutsalo HM, Isomaki H. Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid. Clin Rheumatol 1983;2:233-6
42. Higgens CS, Scott JT. The uricosuric action of azapropazone: dose-response and comparison with probenecid. Br J Clin Pharmacol 1984;18:439-43
43. Lyfar V, Fernandes L, Thornton E, Cook JG. A study of the hypouricaemic effect of tiaprofenic acid. Ann Clin Biochem 1988;25:595-600
44. Barradas MA, Gill DS, Fonseca VA, Mikhailidis DP, Dandona P. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988;18:399-404
45. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. J Am Med Assoc 2004;291:844-50
46. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int [in press]
47. Hoieggen A, Alderman MH, Kjeldsen SE, et al. [LIFE Study Group]. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9